Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.
about
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelComparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft modelsStructure-based design and synthesis of a bivalent iminobiotin analog showing strong affinity toward a low immunogenic streptavidin mutantStructure-based design of a streptavidin mutant specific for an artificial biotin analogueRadioimmunotherapy of human tumoursReduced antibody response to streptavidin through site-directed mutagenesisDesigned heterodimerizing leucine zippers with a ranger of pIs and stabilities up to 10(-15) MPre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinomaDevelopment of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.A modular IgG-scFv bispecific antibody topology.Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas.Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.Differentiation between temporary and real non-clearability of biotinylated IgG antibody by avidin in miceDesign and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.A novel Doxorubicin prodrug with controllable photolysis activation for cancer chemotherapyPretargeted radioimmunotherapy for hematologic and other malignanciesImplications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins.Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.Novel radiolabeled antibody conjugates.The use of radioimmunoconjugates in stem cell transplantation.Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy.Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinomaSuccessful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue.Cancer radioimmunotherapy.Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.Antibody-based treatment of acute myeloid leukaemia.90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.Radioimmunotherapy with engineered antibodies.Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomasSingle reporter for targeted multimodal in vivo imagingComparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.Cancer Imaging and Therapy with Bispecific Antibody Pretargeting.(124)I-huA33 antibody PET of colorectal cancer.Radiotargeting agents for cancer therapy.Tailoring antibodies for radionuclide delivery.Advances in radioimmunotherapy in the age of molecular engineering and pretargeting.Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.
P2860
Q24629826-C16FB6FE-DD4B-4F72-AE4F-DA76F5363909Q27311386-88EE84C8-4186-45C8-A5BC-F87AF58AF5ACQ27697299-26053CA5-32E0-43F4-8030-9EA04C2C98B6Q27697883-B084E2A7-B6E3-48BC-A640-4E7DA4DBE4BFQ28088825-E684BDC6-F259-4870-8D5C-13E1B9A74DA9Q28364576-E5B68C07-5F65-46A0-BD83-152A17C3DB1DQ28364622-A21BE521-7106-498C-9468-684155599312Q28481572-832B20B5-B605-4301-99AF-CB280955C569Q33301860-C0016A51-5814-40EF-8F48-D0B2E1833286Q33519465-BFFA8EE0-7F5F-4F8E-893C-5A46C48DD691Q33645793-BA5EBC7E-CF8D-4220-B232-CECDFF4658DAQ33645841-5387D491-28F0-4BA7-88B6-544ECE608E12Q33661948-CA49037F-C3B8-478F-8D6E-2372A0114B4CQ33944337-E0BBE4C9-1C8D-4E8C-AFC4-3FEEB76CB360Q34029619-FEF7B468-796A-4A18-858E-B08D6129CEF1Q34044370-80D9ABAC-7AE2-48DF-946F-FF05D55F1E0CQ34113941-138C124B-50AD-4242-A588-EB0B22515D38Q34127850-89FBD35A-CE1F-480D-9560-F4A108051890Q34335207-646E9E42-9899-4F29-9F92-F60CCDFCDF86Q34519414-D8FC8023-E270-449B-A76F-7A8B6B07FDDFQ34631801-DEAE18C8-21E7-4FC3-BD5D-EB4D60DF70AAQ34679582-7B6E9DA6-1353-4459-AA54-D542AFA68CE5Q34731015-6C0E3206-AEAE-4FB5-BE5F-CC3EA2268575Q34762427-42710432-ABC6-4D1C-B5FF-AA6456DCB24CQ35059542-50821074-9372-4299-83AB-AD67E630234BQ35063681-E7911D43-32E6-4108-B699-AC3FC05F8E25Q35070045-586CCA21-C2D8-47D8-A51E-FCD7D8F7CE61Q35589582-DF0CD8BD-1859-4CBD-994A-5FAA949446A1Q35609792-AA7BD56A-C00E-486E-9B2F-D9BA245B551AQ35629379-9B241C1F-F3BC-4C26-B58A-822D0C2CDD62Q35681517-EE11B979-B274-43EE-A946-53AB484659B3Q35828820-676EC517-CE21-4557-AEE8-939D432D6AD3Q35848195-9DC39725-98DC-4DDA-B80E-CE5016280546Q35849837-B5E141CC-E66B-46C2-9C49-49D2CD7A7DB8Q36082355-6CB8281A-E6DB-4D90-93A3-E10279DB0F90Q36088144-5506F94A-45A5-4424-B9F8-8BA7D8A6C738Q36316905-A54A99ED-6877-4747-BC14-EB22802F3CF6Q36349687-3CEF9C8D-F622-4025-B9D4-E06F1D0D97CFQ36391426-73AF9E3F-F059-44B7-8F5B-AD138E848AE3Q36395999-0A5CD9DA-6257-4A19-955C-6CB9FDC10937
P2860
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2000
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cure of human carcinoma xenogr ...... m-90 with negligible toxicity.
@en
Cure of human carcinoma xenogr ...... m-90 with negligible toxicity.
@nl
type
label
Cure of human carcinoma xenogr ...... m-90 with negligible toxicity.
@en
Cure of human carcinoma xenogr ...... m-90 with negligible toxicity.
@nl
prefLabel
Cure of human carcinoma xenogr ...... m-90 with negligible toxicity.
@en
Cure of human carcinoma xenogr ...... m-90 with negligible toxicity.
@nl
P2093
P2860
P356
P1476
Cure of human carcinoma xenogr ...... m-90 with negligible toxicity.
@en
P2093
A R Fritzberg
D B Axworthy
L J Hobson
L J Theodore
L M Gustavson
M D Hylarides
P L Beaumier
R W Mallett
P2860
P304
P356
10.1073/PNAS.97.4.1802
P407
P577
2000-02-01T00:00:00Z